ARTICLE | Clinical News

Origin reports Phase IIb data for plasma-generated nitric oxide in chronic diabetic foot ulcers

February 16, 2018 5:32 PM UTC

In October, Origin Inc. (Princeton, N.J.) reported interim data from the Phase IIb GENESIS trial in patients with chronic diabetic foot ulcers showing that plasma-generated nitric oxide met the primary endpoint of safety. Additionally, the product led to a 95% average reduction in wound size at 12 weeks, with 71% of wounds achieving complete closure...

BCIQ Company Profiles

Origin Inc.